Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Nucleotide Polymorphism Association With Response and Toxic Effects in Patients With Ph+ CP-CML Treated With Bosutinib After Relapse to Previous Treatment

NCT02445742 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT02445742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02445742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Nucleotide Polymorphism Association With Response and Toxic Effects in Patients With Ph+ CP-CML Treated With Bosutinib After Relapse to Previous Treatment
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
June 27, 2019
Enrollment
30 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloblastic leukaemia